Bayer Media Event / September 4, 2025 / 5.30 pm – 6.30 pm CEST

How to Evolve the Standard of Care in nAMD and DME

If you cannot hear any sound, please check the livestream play bar to ensure that the sound on your device is turned on.

Significant advancements have been made in anti-VEGF treatment with long intervals that can reduce the burden of disease for patients living with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the question remains – what characteristics drive a new standard of care?

Global thought leaders in retinal diseases will discuss this important topic based on clinical trial results, real-world evidence and their own experience, with a focus on Eylea (aflibercept) 8 mg at the Bayer Media event, taking place at EURETINA 2025.

Agenda

5.30 pm CEST	Introduction
5.35 pm CEST	Welcome address: The need for ongoing advances in anti‐VEGF therapy
5.40 pm CEST	Spectrum: First global real‐world study with Eylea 8 mg Presentation of early real-world evidence in nAMD and DME
5.50 pm CEST	Redefining care: Exploring a new standard of care in nAMD and DME Moderated panel discussion
6.15 pm CEST	Expert dialogue: Bayer’s ongoing commitment to innovation in ophthalmology
6.25 pm CEST	Event close Reflections and closing remarks

Speakers

Dr. Zoran Hasanbasic

Vice President, Global Medical & Evidence Strategy Lead at Bayer, Switzerland

Prof. Marion Munk

Retina specialist at University Bern, Switzerland

Prof. Oliver Zeitz

Professor of Ophthalmology at Charité Berlin, Germany

Dr. Amit Rakhit

Chief Medical Officer, BlueRock Therapeutics, USA

Event moderation

Melinda Crane

Journalist, Germany

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.